Stoke Therapeutics, Inc.
STOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,377 | $662 | $385 | $629 |
| - Cash | $83 | $101 | $275 | $128 |
| + Debt | $0 | $2 | $2 | $2 |
| Enterprise Value | $1,294 | $563 | $112 | $503 |
| Revenue | $11 | $14 | $159 | $23 |
| % Growth | -23.1% | -91.3% | 601.2% | – |
| Gross Profit | $10 | $14 | $159 | $23 |
| % Margin | 90.7% | 100% | 100% | 100% |
| EBITDA | -$39 | -$27 | $112 | -$13 |
| % Margin | -363.4% | -194.4% | 70.5% | -58% |
| Net Income | -$38 | -$23 | $113 | -$10 |
| % Margin | -360.7% | -170% | 71.2% | -46.4% |
| EPS Diluted | -0.65 | -0.4 | 1.9 | -0.18 |
| % Growth | -62.5% | -121.1% | 1,155.6% | – |
| Operating Cash Flow | -$30 | -$25 | $132 | -$23 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$30 | -$26 | $132 | -$23 |